NEW YORK,
Feb. 22,
2024 /PRNewswire/ -- The Gross Law Firm issues the
following notice to shareholders of Amylyx Pharmaceuticals,
Inc.
Shareholders who purchased shares of AMLX during
the class period listed are encouraged to contact the firm
regarding possible lead plaintiff appointment. Appointment as lead
plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/amylyx-loss-submission-form/?id=67636&from=4
CLASS PERIOD: November 11, 2022 to November 8, 2023
ALLEGATIONS: The complaint
alleges that during the class period, Defendants
issued materially false and/or misleading statements and/or failed
to disclose that: (i) defendants had overstated RELYVRIO's (a dual
UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and
taurursodiol, for the treatment of ALS in adults in the U.S.)
commercial prospects; (ii) patients were discontinuing treatment
with RELYVRIO after six months; (iii) the rate at which new
patients were starting treatment with RELYVRIO was decreasing; (iv)
accordingly, defendants had also overstated RELYVRIO's prescription
rate; (v) defendants attempted to hide the foregoing negative
trends from investors and the market by blocking analysts from
viewing RELYVRIO's prescription data; and (vi) as a result,
Defendants' public statements were materially false and misleading
at all relevant times.
DEADLINE: April 9,
2024 Shareholders should not delay in registering for
this class action. Register your information here:
https://securitiesclasslaw.com/securities/amylyx-loss-submission-form/?id=67636&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you
register as a shareholder who purchased shares of AMLX during the
timeframe listed above, you will be enrolled in a portfolio
monitoring software to provide you with status updates throughout
the lifecycle of the case. The deadline to seek to be a lead
plaintiff is April 9, 2024. There is
no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is
a nationally recognized class action law firm, and our mission is
to protect the rights of all investors who have suffered as a
result of deceit, fraud, and illegal business
practices. The Gross Law Firm is committed to ensuring that
companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of
investors who incurred losses when false and/or misleading
statements or the omission of material information by a company
lead to artificial inflation of the company's stock. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amylyx-pharmaceuticals-inc-class-action-the-gross-law-firm-reminds-amylyx-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-april-9-2024--amlx-302068230.html
SOURCE The Gross Law Firm